NEW YORK, NY / ACCESSWIRE / January 7, 2022 / Laxxon Medical Corporation announced today that management would conduct one-on-one meetings at the 24th Annual Needham Growth Conference, which will be held virtually from Jan 10-14, 2022.
About Laxxon Medical Corporation
Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture, and commercialization of pharmaceutical dosage forms.
With Laxxon Medical's innovative SPID®-Technology (Screen Printing Innovational Drug Technology), it is possible for the first time to develop oral, transdermal, and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients within the printed units yielding dosage forms with the tailored release of active ingredients.
To learn more about Laxxon Medical's disruptive 3D screen printing technology, visit www.laxxonmedical.com.
Frances Hoggard, Public Relations Manager email@example.com
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients. We aim to establish SPID®-Technology as a manufacturing process with the individual and the pharmaceutical partner in mind.